Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease

Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.

Scrip Asks, Part 4
• Source: Alamy

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the coming year. Biopharma industry executives surveyed by Scrip also flagged up rare diseases, neurology and – of course – COVID-19 as hot areas to watch in 2022.

Jason Bernstein, director and head of medical communications strategy at medical information app provider epocrates, flagged up two key trends...

More from Scrip Asks

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data Science

 

More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.

Scrip Asks… What Does 2025 Hold For Biopharma? Part 3: Impacts Of Political Change In US And Beyond

 

What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?

More from Scrip

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By 

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.